JP2019507134A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507134A5
JP2019507134A5 JP2018540013A JP2018540013A JP2019507134A5 JP 2019507134 A5 JP2019507134 A5 JP 2019507134A5 JP 2018540013 A JP2018540013 A JP 2018540013A JP 2018540013 A JP2018540013 A JP 2018540013A JP 2019507134 A5 JP2019507134 A5 JP 2019507134A5
Authority
JP
Japan
Prior art keywords
composition
compound
administered
amount
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507134A (ja
JP6964593B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015237 external-priority patent/WO2017132445A1/en
Publication of JP2019507134A publication Critical patent/JP2019507134A/ja
Publication of JP2019507134A5 publication Critical patent/JP2019507134A5/ja
Application granted granted Critical
Publication of JP6964593B2 publication Critical patent/JP6964593B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540013A 2016-01-27 2017-01-27 ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン Expired - Fee Related JP6964593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287858P 2016-01-27 2016-01-27
US62/287,858 2016-01-27
PCT/US2017/015237 WO2017132445A1 (en) 2016-01-27 2017-01-27 Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor

Publications (3)

Publication Number Publication Date
JP2019507134A JP2019507134A (ja) 2019-03-14
JP2019507134A5 true JP2019507134A5 (enExample) 2020-03-12
JP6964593B2 JP6964593B2 (ja) 2021-11-10

Family

ID=59398691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540013A Expired - Fee Related JP6964593B2 (ja) 2016-01-27 2017-01-27 ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン

Country Status (6)

Country Link
US (2) US20190111053A1 (enExample)
EP (1) EP3407887B1 (enExample)
JP (1) JP6964593B2 (enExample)
CN (1) CN109475543A (enExample)
CA (1) CA3051828A1 (enExample)
WO (1) WO2017132445A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
JP7187023B6 (ja) 2015-05-15 2023-01-05 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンプロドラッグ
US20190240290A1 (en) * 2016-08-04 2019-08-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Companion diagnostic for combination lenalidomide and erythropoietin treatment
AU2017370731B2 (en) 2016-12-08 2022-06-02 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030617A2 (en) 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer therapy with cantharidin and cantharidin analogs
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
KR20160004299A (ko) * 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
WO2016014778A1 (en) * 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
US20160074390A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor

Similar Documents

Publication Publication Date Title
Blichfeldt et al. Metronidazole in Crohn's disease: a double blind cross-over clinical trial
RU2005140285A (ru) Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения
RU2014142267A (ru) Лекарственное средство для лечения острого миелоидного лейкоза (омл)
MD3310809T2 (ro) Formularea anticorpului anti-CGRP
JP2018521964A5 (enExample)
JP2019517542A5 (enExample)
JP2011225596A5 (enExample)
EP3383385B2 (en) Melflufen dosage regimens for cancer
JP2018087228A (ja) がんのためのグルフォスファミド組み合わせ療法
JPWO2014038630A1 (ja) セシウム排泄剤、有害金属排泄剤、飲食品、飼料および医薬品
Nuraini et al. Effects of Iron accumulation on dental caries, gingivitis, and candida albicans infection in children with beta thalassemia major: a narrative review
Boccadoro et al. Standard chemotherapy for myelomatosis: an area of great controversy
Hajigholami et al. Comparing the efficacy of Dexeroyx (Osveral) and Deferoxamine (Desferal) in reducing serum ferritin level in patients with thalassemia major
JP2024517318A5 (enExample)
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
Arzoo et al. Efficacy of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in the Treatment of Iron Deficiency Anemia of Pregnancy: Intravenous Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia
Oh et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis
Noguerado-Mellado et al. Anaphylactic shock due to brentuximab-vendotin confirmed by skin test and in vitro tests
Ho et al. 2′-Deoxycoformycin (Pentostatin) in hairy cell leukemia: response in patients refractory to interferon alpha
Vanholder et al. Cefodizime: enhancement of depressed phagocytosis-associated respiratory burst activity in chronic uremic patients
Bakar et al. Salmonella related mycotic aneurysm with psoas and paraortic abscess treated conservatively
Azzarà et al. Morphological features following G-CSF treatment
Saba et al. Supportive Care in Myelodysplastic Syndrome
JP2012025734A (ja) 骨髄異形性症候群を治療するための組成物および方法
González et al. Intravenous iron